AlzChem Group AG (ETR:ACT)
Germany · Delayed Price · Currency is EUR | Market Cap | 1.64B +57.8% |
| Revenue (ttm) | 581.10M +4.0% |
| Net Income | 66.82M +18.3% |
| EPS | 6.61 +18.9% |
| Shares Out | 10.12M |
| PE Ratio | 24.51 |
| Forward PE | 23.87 |
| Dividend | 2.10 (1.30%) |
| Ex-Dividend Date | May 6, 2026 |
| Volume | 24,789 |
| Average Volume | 22,436 |
| Open | 161.70 |
| Previous Close | 161.90 |
| Day's Range | 160.20 - 167.50 |
| 52-Week Range | 115.80 - 190.00 |
| Beta | 0.37 |
| RSI | 37.92 |
| Earnings Date | Apr 30, 2026 |
About AlzChem Group AG
AlzChem Group AG, together with its subsidiaries, develops, produces, and markets a range of chemical specialties in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The Specialty Chemicals segment sells specialty chemical products that are used in the chemical, food, animal feed, defence technology, and renewable energies industries. This segment manufactures composite materials and adhesives, as well as silico... [Read more]
Financial Performance
In 2025, AlzChem Group AG's revenue was 575.05 million, an increase of 2.06% compared to the previous year's 563.44 million. Earnings were 63.46 million, an increase of 17.35%.
Financial StatementsNews
AlzChem Group AG Earnings Call Transcript: Q1 2026
Revenue and profitability grew strongly in Q1 2026, driven by specialty ingredients, with EBITDA up 18% and net income up 23% year-over-year. Major growth projects are on track, and full-year guidance is confirmed despite ongoing macroeconomic and geopolitical risks.
EQS-AFR: Alzchem Group AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Alzchem Group AG / Preliminary announcement on the disclosure of financial statements Alzchem Group AG: Preliminary announcement of the publication of f...
AlzChem Group AG Earnings Call Transcript: H2 2025
Sales and EBITDA grew year-over-year, driven by specialty chemicals and strong creatine demand, with record margins and robust cash flow. Major investments in creatine and defense capacity set the stage for double-digit growth from 2027.
AlzChem Group AG Earnings Call Transcript: Q3 2025
Specialty chemicals drove strong Q3 and nine-month growth, with EBITDA up 12% and margin at 20.3%. Capacity expansions, new product launches, and a robust outlook for full-year sales and earnings highlight continued momentum, despite FX and energy cost risks.
AlzChem Group AG Earnings Call Transcript: Q2 2025
Sales and EBITDA grew in H1 2025, led by Specialty Chemicals, especially creatine and custom synthesis. CapEx and customer grants support major expansions, while risks include energy costs, Chinese competition, and regulatory uncertainty. Guidance for 2025 is confirmed.
AlzChem Group AG Earnings Call Transcript: Q1 2025
Specialty chemicals drove Q1 2025 growth with higher EBITDA and margin, offsetting declines in basics and intermediates. Major investments and customer prepayments strengthened cash flow, and full-year guidance for record sales and EBITDA is confirmed.
AlzChem Group AG Earnings Call Transcript: Q4 2024
Record sales and EBITDA were achieved in 2024, driven by specialty chemicals, with strong cash flow and a robust balance sheet. 2025 guidance anticipates further growth, major CapEx, and continued focus on specialty segments, while managing energy and competitive risks.
AlzChem Group AG Earnings Call Transcript: Q3 2024
Q3 saw strong revenue and EBITDA growth, driven by specialty chemicals, with net income up 66% year-over-year. Major investments in Germany and the U.S. are pre-financed, supporting future growth, while guidance for 2024 is confirmed with EBITDA expected above €100 million.